1,938 active funding opportunities
Funds confirmatory clinical trials testing non-pharmacological and pharmacological interventions for mental disorders, focusing on therapeutic mechanisms and unmet needs.
Supports pilot research developing and testing novel psychosocial interventions for mental disorders with clinical trials required.
Funds early stage clinical trials of novel drugs and neuromodulatory devices for psychiatric disorders, focusing on safety, target engagement, and efficacy.
Supports early stage clinical trials testing pharmacologic or device-based interventions for mental disorders using mechanism-focused experimental therapeutics.
Funds early career research on hearing, balance, smell, taste, voice, speech, or language to generate preliminary data for R01 grants.
Funds early stage clinical trials testing pharmacologic or device-based interventions for mental disorders, focusing on mechanisms of action and clinical effects.
Funds vision-related research using secondary data analysis and statistical method development. Clinical trials not allowed.
Funds cooperative agreements for clinical trials targeting communication disorders requiring FDA oversight or establishing efficacy.
Supports innovative translational research projects that accelerate treatment development and dissemination across diseases.
Supports early-stage development of novel informatics tools to advance cancer research across biology, treatment, detection, and epidemiology.
Supports assay development and screening to identify neurotherapeutic agents for neurological and neuromuscular disorders.
Funds development of animal and ex vivo models to improve translational neurotherapeutic discovery for neurological disorders.
Supports studies to demonstrate biological activity of neurotherapeutic agents for neurological disorders, advancing translational research to meet neurotherapeutic network criteria.
Supports planning and preparatory studies for clinical trials improving cancer prevention, screening, treatment symptom management, and survivor outcomes.
Funds multidisciplinary programs to develop new drugs and neurostimulation devices for mental and substance use disorders, encouraging academia-industry partnerships.
Supports discovery and development of new drugs and neurostimulation devices to treat mental and substance use disorders with academia-industry partnerships.
Funds preparatory studies to improve design and feasibility of cancer prevention and control clinical trials.
Funds small scale biomedical research and minimal risk clinical trials at underfunded health professional and graduate schools.
Funds early-stage development of novel Alzheimer's drug candidates including pre-clinical studies and Phase I trials.
Supports HIV/AIDS research aligned with NIDDK mission and NIH HIV/AIDS priorities, clinical trial optional.
Supports renewal of existing NINDS clinical trial cooperative agreements needing more time and resources to complete trials.
Supports development of computational tools and models to analyze dynamic brain circuits and advance brain disorder treatments.
Funds established investigators to build research capacity and mentorship in aging and Alzheimer's Disease without leading independent clinical trials.
Supports NINDS intramural neurologist- and neurosurgeon-scientists transitioning to independent research and clinical faculty roles.
